research team photo

Gaining new knowledge about Huntington's disease is a critically important part of developing more effective treatments for HD and ultimately finding a cure. The way we discover this new knowledge is through clinical trials and other research studies. 

Opportunities and requirements for participation may vary considerably from one trial or study to another. If you are interested in volunteering, our research staff will be happy to help you identify studies you may be eligible for.

We are always looking for more participants, so please feel free to contact our research coordinator if you would like more information. Scroll down the page to learn about our research projects at UC Davis and for additional resources.

Speak to us about research!
Fernando Rodriguez
HD Clinical Research Coordinator

Clinical Studies and Research at UC Davis

 
Enroll-HD
Currently Enrolling Participants
Enroll-HD is a worldwide observational study for Huntington's disease families. Study visits occur once a year and include a neurological exam, blood sample collection, and other assessments to measure attention, memory, mood, and quality of life.

Learn more about Enroll-HD

Contact UC Davis about Enroll-HD
 Fernando Rodriguez, study coordinator
 916-734-7706

Change hd-logo

ChANGE HD
Currently Enrolling Participants
The purpose of this research study is to examine the structure and functioning of the brain in young people ages 6-30 who have a family history of Huntington’s Disease (HD). We hope this study will help explain how the gene responsible for HD affects brain development, and we hope to find a way to identify the best time for gene therapy during development. Participants in this study will be asked to complete one research visit per year for either three or four years.  Each visit will take 6-8 hours to complete and will include: Cognitive assessment, Motor examinations, Questionnaires, MRI brain scan, Vital signs, and blood draw.

Contact UC Davis about ChANGE HD
 Fernando Rodriguez, study coordinator
 916-734-7706

Generation HD2 logo
Generation HD2
Currently Enrolling

The purpose of this study is to compare the effects, good or bad, of two different doses of tominersen versus placebo to select a dose that could potentially benefit individuals with early HD. Tominersen is from a group of drugs known as antisense oligonucleotides, which are short man‑made stretches of DNA that stop the "messenger" RNA from instructing cells to make proteins. Tominersen has been shown to lower levels of this toxic protein in previous clinical trials by interfering with its production. You will have clinic visits approximately every 16 weeks while you are receiving treatment. Visits may last up to 8 hours. Your total time in this part of the study is expected to be between 16 and 24 months.

Contact UC Davis about Generation HD2
 Fernando Rodriguez, study coordinator
 916-734-7706

Dimension study logo
DIMENSION Study
Currently Enrolling

The DIMENSION Study is evaluating the safety and effect on cognitive symptoms of an investigational oral drug in adults with early Huntington’s disease. Cognitive symptoms may include difficulty paying attention or trouble thinking through steps of an activity or complex problems. The study lasts up to 20 weeks and includes 9 visits to the study office. To be eligible for the study you must be 25 to 65 years of age. If you are eligible to participate in the study, you will be randomly assigned to receive one of the study treatments, either Sage-718 or placebo. You will have an equal chance of being given each treatment.

Contact UC Davis about the DIMENSION Study
 Fernando Rodriguez, study coordinator
 916-734-7706

Purview study logo
PURVIEW Study
Currently Enrolling

The PURVIEW Study is an open-label study which means all participants will be receiving SAGE-718 for 365 days. There is no placebo group. If you took part in a previous SAGE-718 HD Study (protocol number 718-CIH-201/DIMENSION) within the past 7 days, you will be in this study for approximately 13 months.

Contact UC Davis about the PURVIEW Study
 Fernando Rodriguez, study coordinator
 916-734-7706

Proof HD logo

PROOF-HD
Closed to enrollment

The purpose of PROOF-HD is to find out if Pridopidine is a safe and effective drug and to find out the effect of Pridopidine on every day functioning and daily activities in people with early stage HD. Participants have a 50/50 chance of receiving study drug (Pridopidine) versus placebo. Participants must be at least 25 years old and have a diagnosis of Stage 1 or 2 HD.  Subjects must agree to participate in 8 in person visits, 6 phone calls, and 4 virtual visits over 86 weeks.  Visits include assessments such as neurological and physical exams, cognitive tests, motor assessments, blood collection, and more.

Learn more about Proof-HD

Contact UC Davis about PROOF-HD
 Fernando Rodriguez, study coordinator
 916-734-7706


find us on facebook